

- 5 Lambert RJW, *et al.* Theory of antimicrobial combinations: biocide mixtures—synergy or additions? *J Appl Microbiol* 2003; **94**: 747–759.
- 6 Gadalla MAF, *et al.* Effect of electrolytes on the solubility and solubilization of chlorocresol. *Pharmazie* 1974; **29**: 105–107.
- 7 McEwan JS, Macmorran GH. The compatibility of some bactericides. *Pharm J* 1947; **158**: 260–262.
- 8 Yousef RT, *et al.* Effect of some pharmaceutical materials on the bactericidal activities of preservatives. *Can J Pharm Sci* 1973; **8**: 54–56.
- 9 McCarthy TJ. Dissolution of chlorocresol from various pharmaceutical formulations. *Pharm Weekbl* 1975; **110**: 101–106.
- 10 Kazmi SJA, Mitchell AG. Preservation of solubilized and emulsified systems I: correlation of mathematically predicted preservative availability with antimicrobial activity. *J Pharm Sci* 1978; **67**: 1260–1266.
- 11 Kazmi SJA, Mitchell AG. Preservation of solubilized and emulsified systems II: theoretical development of capacity and its role in antimicrobial activity of chlorocresol in cetomacrogol-stabilized systems. *J Pharm Sci* 1978; **67**: 1266–1271.
- 12 McCarthy TJ. Interaction between aqueous preservative solutions and their plastic containers III. *Pharm Weekbl* 1972; **107**: 1–7.
- 13 Roberts MS, *et al.* The storage of selected substances in aqueous solution in polyethylene containers: the effect of some physicochemical factors on the disappearance kinetics of the substances. *Int J Pharm* 1979; **2**: 295–306.
- 14 McCarthy TJ. Interaction between aqueous preservative solutions and their plastic containers. *Pharm Weekbl* 1970; **105**: 557–563.
- 15 Kurup TRR, *et al.* Preservative requirements in emulsions. *Pharma Acta Helv* 1992; **67**: 204–208.
- 16 Kurup TRR, *et al.* Effect of surfactants on the antimicrobial activity of preservatives. *Pharma Acta Helv* 1991; **66**: 274–280.
- 17 Sznitowska M, *et al.* Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. *Eur J Pharm Sci* 2002; **15**: 489–495.
- 18 Summers QA, *et al.* A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions. *Br J Clin Pharmacol* 1991; **31**: 204–206.
- 19 Smolinske SC. *Handbook of Food, Drug and Cosmetic Excipients*. Boca Raton, FL: CRC Press, 1992: 87–90.
- 20 Zondlo M. Final report on the safety assessment of *p*-chloro-*m*-cresol. *J Toxicol* 1997; **16**: 235–268.
- 21 Jong CT, *et al.* Contact sensitivity to preservatives in the UK, 2004–2005: results of multicenter study. *Contact Dermatitis* 2007; **57**: 165–168.
- 22 Burry JN, *et al.* Chlorocresol sensitivity. *Contact Dermatitis* 1975; **1**: 41–42.
- 23 Andersen KE, Hamann K. How sensitizing is chlorocresol? Allergy tests in guinea pigs vs. the clinical experience. *Contact Dermatitis* 1984; **11**: 11–20.
- 24 Agu RU, *et al.* Effects of pharmaceutical compounds on ciliary beating in human nasal epithelial cells: a comparative study of cell culture models. *Pharm Res* 1999; **16**: 1380–1385.
- 25 Andersen A. Final report on the safety assessment of sodium *p*-chloro-*m*-cresol, *p*-chloro-*m*-cresol, chlorothymol, mixed cresols, *m*-cresol, *o*-cresol, *p*-cresol, isopropyl cresols, thymol, *o*-cymen-5-ol, and carvacrol. *Int J Toxicol* 2006; **25**(Suppl. 1): 29–127.
- 26 Palanichamy S, *et al.* Preservation of sodium chloride eye lotion BPC against contamination with *Pseudomonas aeruginosa*. *Indian Drugs* 1982; **19**: 153–155.
- 27 Palanichamy S, *et al.* Preservation of compound zinc sulfate eye lotion BPC 1963 against contamination with *Pseudomonas aeruginosa*. *Indian J Hosp Pharm* 1982; **19**: 64–65.
- 28 Hancock BW, Naysmith A. Hypersensitivity to chlorocresol-preserved heparin. *Br Med J* 1975; **3**: 746–747.
- 29 Ainley EJ, *et al.* Adverse reaction to chlorocresol-preserved heparin [letter]. *Lancet* 1977; **i**: 705.
- 30 Lewis RJ, ed. *Sax's Dangerous Properties of Industrial Materials*, 12th edn. New York: Wiley, 2012: 971.
- 31 Japanese Pharmaceutical Excipients Council. *Japanese Pharmaceutical Excipients 2004*. Tokyo: Yakuji Nippo, 2004: 171.
- 32 Japanese Pharmaceutical Excipients Council. *Japanese Pharmaceutical Excipient Directory*. Tokyo: Yakuji Nippo, 2005: 96.
- 33 Wappler F, *et al.* Multicenter evaluation of *in vitro* contracture testing with bolus administration of 4-chloro-*m*-cresol for diagnosis of malignant hyperthermia susceptibility. *Eur J Anaesth* 2003; **20**: 528–536.
- 34 Anetseder M, *et al.* The impact of 4-chloro-*m*-cresol in heparin formulation on malignant hyperthermia: *in vitro* and *in vivo*. *Acta Anaesthes Scand* 2000; **44**: 338–342.

20 General References

Aldon Corp. Material safety data sheet: Chlorocresol, 1999. Verschueren K. *Handbook of Environmental Data on Organic Chemicals*, vol. 1–2. 4th edn. New York: John Wiley & Sons, 2001: 491.

21 Author

S Nema.

22 Date of Revision

4 May 2017.

Chlorodifluoroethane (HCFC)

1 Nonproprietary Names

None adopted.

2 Synonyms

1,1-Difluoro-1-chloroethane; *Dymel 142b*; *Genetron 142b*; HCFC 142b; propellant 142b; R-142b; refrigerant 142b; *Solkane 142b*.


3 Chemical Name and CAS Registry Number

1-Chloro-1,1-difluoroethane [75-68-3]

4 Empirical Formula and Molecular Weight

C₂H₃ClF₂ 100.50

5 Structural Formula



6 Functional Category

Aerosol propellant.